Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Go back to Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma| (NASDAQ: LEGN) | Delayed: 29.35 +1.42 (5.08%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.93 | 52 Week High | $ | |||
| Open | $28.38 | 52 Week Low | $ | |||
| Day High | $29.46 | P/E | N/A | |||
| Day Low | $28.10 | EPS | $ | |||
| Volume | 1,608,925 | |||||
